Sivik Global Healthcare LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 17,500 shares of the company’s stock, valued at approximately $2,721,000.
Other large investors also recently bought and sold shares of the company. D.A. Davidson & CO. lifted its position in shares of IDEXX Laboratories by 160.4% during the second quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock worth $100,000 after acquiring an additional 385 shares in the last quarter. Sun Life Financial INC lifted its position in shares of IDEXX Laboratories by 9,085.7% during the second quarter. Sun Life Financial INC now owns 643 shares of the company’s stock worth $104,000 after acquiring an additional 636 shares in the last quarter. BB&T Investment Services Inc. purchased a new stake in shares of IDEXX Laboratories during the second quarter worth $104,000. Capital Advisors Ltd. LLC purchased a new stake in shares of IDEXX Laboratories during the second quarter worth $128,000. Finally, Coastline Trust Co purchased a new stake in shares of IDEXX Laboratories during the second quarter worth $202,000. Hedge funds and other institutional investors own 88.41% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2017/11/23/17500-shares-in-idexx-laboratories-inc-idxx-acquired-by-sivik-global-healthcare-llc.html.
In related news, CEO Jonathan W. Ayers sold 18,000 shares of the stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $153.61, for a total value of $2,764,980.00. Following the transaction, the chief executive officer now owns 1,064,573 shares of the company’s stock, valued at $163,529,058.53. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Jonathan W. Ayers sold 13,000 shares of the stock in a transaction on Monday, August 28th. The shares were sold at an average price of $150.79, for a total value of $1,960,270.00. Following the completion of the transaction, the chairman now directly owns 1,044,034 shares in the company, valued at approximately $157,429,886.86. The disclosure for this sale can be found here. In the last ninety days, insiders sold 121,000 shares of company stock worth $18,334,330. Insiders own 2.77% of the company’s stock.
Several equities research analysts have issued reports on IDXX shares. CL King upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 target price on the stock in a research report on Friday, July 28th. BidaskClub cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Stifel Nicolaus reaffirmed a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a report on Wednesday, August 2nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a report on Tuesday, August 22nd. Finally, Bank of America Corporation raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target on the stock in a report on Wednesday, August 23rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $173.67.
IDEXX Laboratories, Inc. (IDXX) traded down $1.53 during trading on Thursday, hitting $154.06. 285,300 shares of the stock traded hands, compared to its average volume of 708,148. The company has a market capitalization of $13,300.00, a PE ratio of 52.39, a P/E/G ratio of 2.35 and a beta of 0.46. IDEXX Laboratories, Inc. has a 52-week low of $113.47 and a 52-week high of $173.01. The company has a current ratio of 0.95, a quick ratio of 0.77 and a debt-to-equity ratio of -12.48.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.05. The firm had revenue of $492.00 million for the quarter, compared to analysts’ expectations of $492.94 million. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The business’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.62 earnings per share. equities research analysts forecast that IDEXX Laboratories, Inc. will post 3.24 EPS for the current year.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.